171 related articles for article (PubMed ID: 38199172)
21. A Reappraisal of Superficial Pleomorphic Liposarcoma.
Berg SH; Massoud CM; Jackson-Cook C; Boikos SA; Smith SC; Mochel MC
Am J Clin Pathol; 2020 Aug; 154(3):353-361. PubMed ID: 32525520
[TBL] [Abstract][Full Text] [Related]
22. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
[TBL] [Abstract][Full Text] [Related]
23. What's new in adipocytic neoplasia?
Creytens D
Virchows Arch; 2020 Jan; 476(1):29-39. PubMed ID: 31501988
[TBL] [Abstract][Full Text] [Related]
24. Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review.
Thway K
Semin Diagn Pathol; 2019 Mar; 36(2):112-121. PubMed ID: 30852045
[TBL] [Abstract][Full Text] [Related]
25. [Myxoid liposarcoma and pleomorphic liposarcoma: cyto-histological correlations].
Capitanio G; Blandamura S; Barbazza R; Caldart T; Dalla Palma P
Pathologica; 1989; 81(1075):543-9. PubMed ID: 2641156
[TBL] [Abstract][Full Text] [Related]
26. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.
Massi D; Beltrami G; Capanna R; Franchi A
Eur J Surg Oncol; 2004 Dec; 30(10):1131-6. PubMed ID: 15522563
[TBL] [Abstract][Full Text] [Related]
27. Immunolocalization of heparin-binding EGF-like growth factor (HB-EGF) as a possible immunotarget in diagnosis of some soft tissue sarcomas.
Musumeci G; Travali S; Di Rosa M; Scuderi R; Failla A; Imbesi R; Castrogiovanni P
Acta Histochem; 2013 Sep; 115(7):719-27. PubMed ID: 23597914
[TBL] [Abstract][Full Text] [Related]
28. Spindle cell liposarcoma with a TRIO-TERT fusion transcript.
Suster DI; Deshpande V; Chebib I; Taylor MS; Mullen J; Bredella MA; Nielsen GP
Virchows Arch; 2019 Sep; 475(3):391-394. PubMed ID: 30793229
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma.
Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Osaki J; Adachi Y; Ono T; Tsuchiya R; Sato C; Iwata S; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2023 Jan; 36(1):468-475. PubMed ID: 36436139
[TBL] [Abstract][Full Text] [Related]
30. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up.
Pearlstone DB; Pisters PW; Bold RJ; Feig BW; Hunt KK; Yasko AW; Patel S; Pollack A; Benjamin RS; Pollock RE
Cancer; 1999 Jan; 85(1):85-92. PubMed ID: 9921978
[TBL] [Abstract][Full Text] [Related]
31. Head pleomorphic sarcoma showing murine double minute 2 amplification without a well-differentiated liposarcoma component in a pediatric patient.
Akaihata M; Takahashi I; Kakuda Y; Kawata T; Mukaigawa T; Onitsuka T; Murayama S; Ishida Y
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1774. PubMed ID: 36572546
[TBL] [Abstract][Full Text] [Related]
32. Lipomatous tumors.
Weiss SW
Monogr Pathol; 1996; 38():207-39. PubMed ID: 8744279
[TBL] [Abstract][Full Text] [Related]
33. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines.
Salawu A; Fernando M; Hughes D; Reed MW; Woll P; Greaves C; Day C; Alhajimohammed M; Sisley K
Br J Cancer; 2016 Oct; 115(9):1058-1068. PubMed ID: 27560552
[TBL] [Abstract][Full Text] [Related]
34. Orbital pleomorphic liposarcoma in an eight-year-old boy.
Rudzinski E; Mawn L; Kuttesch J; Wushensky C; Wills M
Pediatr Dev Pathol; 2011; 14(4):339-44. PubMed ID: 21417910
[TBL] [Abstract][Full Text] [Related]
35. A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.
Yu PY; Balkhi MY; Ladner KJ; Alder H; Yu L; Mo X; Kraybill WG; Guttridge DC; Iwenofu OH
Lab Invest; 2016 Apr; 96(4):481-91. PubMed ID: 26878133
[TBL] [Abstract][Full Text] [Related]
36. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.
Bhalla AD; Landers SM; Singh AK; Landry JP; Yeagley MG; Myerson GSB; Delgado-Baez CB; Dunnand S; Nguyen T; Ma X; Bolshakov S; Menegaz BA; Lamhamedi-Cherradi SE; Mao X; Song X; Lazar AJ; McCutcheon IE; Slopis JM; Ludwig JA; Lev DC; Rai K; Torres KE
Lab Invest; 2022 Jun; 102(6):658-666. PubMed ID: 35228656
[TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
38. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells.
Nyström H; Jönsson M; Nilbert M; Carneiro A
Acta Oncol; 2023 Jan; 62(1):33-39. PubMed ID: 36786033
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):688-697. PubMed ID: 33205363
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes.
Sreekantaiah C; Karakousis CP; Leong SP; Sandberg AA
Cancer; 1992 May; 69(10):2484-95. PubMed ID: 1568170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
